Traws Pharma, Inc. financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Traws Pharma, Inc. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2024
Revenue	5.55	0.79	1.23	2.18	0.23	0.23	0.23	0.23	0.23	2.79
Research and development	20.1	19.1	16.9	15.5	16.9	7.3	11.4	11.4	12.8	12.1
General and administrative	9.18	7.41	7.59	8.35	8.33	9.43	8.45	9.09	12.3	8.52
Operating expenses	29.2	26.5	24.5	23.9	25.2	16.7	19.9	20.5	143	20.7
Operating income	-23.7	-25.7	-23.3	-21.7	-25	-16.5	-19.6	-20.3	-142	-17.9
Interest income							0.65	1.39	0.51	0.46
Other non-operating income	0.06	0.03	1.15	0.14	0.05	0.01	0.66	1.35	0.29	0.48
Pre-tax income	-19.7	-24.1	-20.5	-21.5	-25.2	-16.2	-19	-18.9	-167	9.17
Income tax	0.01	0.01	-0.12	0.01	0
Net income to minority interests			0.16
Net income	-19.7	-24.1	-20.6	-21.5	-25.2	-16.2	-19	-18.9	-167	9.17
EBITDA	-23.6	-25.6	-23.2	-21.7	-25	-16.5	-19.6	-20.3	-142	-17.8
EPS, basic	-25,856.00	-15,607.00	-1,940.00	-579.17	-54.42	-24.07	-22.82	-22.57	-35.21	0.83
EPS, diluted	-25,856.00	-15,607.00	-1,940.00	-579.17	-54.42	-24.07	-22.82	-22.57	-35.21	0.82
Shares, basic (weighted)	0	0	0.01	0.04	0.46	0.67	0.83	0.84	1.55	8.23
Shares, diluted (weighted)	0	0	0.01	0.04	0.46	0.67	0.83	0.84	1.55	8.38

Balance sheet

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2024
Cash and equivalents	21.4	4.02	17	22.7	19	55.1	38.5	20.6	21.3	3.82
Receivables	0.03	0.06	0.04	0.1	0.04	0.03	0.03	0.02	1.77	3.79
Other current assets	0.07	0.08	0.07	0.14	0.18	0.04	0.04	0.4	0.18	0.09
Total current assets	23.1	4.9	17.8	23.5	19.8	55.4	39.3	22.7	25	7.98
Property, plant and equipment	0.15	0.06	0.01	0.05	0.05	0.04	0.02	0.02	0.01	0.01
Intangible assets										2.53
Other non-current assets	0.01	0.01	0.15	0.15	0.15	0.01	0	0	0	0.1
Total assets	23.2	4.98	17.9	23.7	20	55.5	39.4	22.7	25	10.6
Accounts payable	5.32	6.19	4.04	4.27	4.83	2.76	3.86	5.62	8.19	5.65
Accrued liabilities	1.57	1.26	4.17	3.8	4.96	3.13	3.96	3.38	3.12	5.49
Deferred revenue	0.46	0.46	0.23	0.23	0.23	0.23	0.23	0.23	0.23
Total current liabilities	10.2	9.98	8.44	8.29	10	6.12	8.05	9.22	11.5	11.1
Total liabilities	18.1	15.8	12.5	12.1	13.8	9.36	11.1	12	56.6	11.2
Paid-in capital	342	351	387	414	435	491	492	493	618	639
Retained earnings	-338	-362	-382	-403	-429	-445	-464	-483	-649	-640
Other comprehensive income	-0.03	0	-0.01	-0.02	0.01	-0.01	-0.03	-0.02	-0.04	0.01
Shareholders' equity	4.3	-11.7	5.39	11.6
Minority interests	0.83	0.83
Total equity	5.13	-10.9	5.39	11.6	6.18	46.1	28.3	10.7	-31.6	-0.63
Total liabilities and equity	23.2	4.98	17.9	23.7	20	55.5	39.4	22.7	25	10.6
Shares outstanding	0	0	0.01	0.29	0.49	0.83	0.83	0.84	3.65	9.07

Cash flow statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2024
Net income	-19.7	-24.1	-20.4	-21.5	-25.2	-16.2	-19	-18.9	-167	9.17
Depreciation and amortization	0.1	0.09	0.06	0.01	0.01	0.01	0.01	0.02	0.01	0.06
Stock-based compensation	3.93	1.71	1.15	1.05	0.37	0.58	1.17	1.3	1.39	0.73
Deferred income tax	0		-0.14
Change in receivables	1.47	-0.03	0.02	-0.06	0.06	0.01	-0	0.01	-1.75	-2.03
Change in payables	1.9	0.86	-1.45	0.23	0.56	-2.08	1.1	1.76	0.65	-0.61
Cash from operations	-15.8	-23.8	-22.7	-20.8	-23.1	-19.5	-16.3	-17.9	-29.8	-18.2
Capital expenditures				-0.06	-0.02			-0.01	-3.65	-2.59
Cash from investing				-0.06	-0.02			-0.01	-3.65	-2.59
Stock issued	0		35.1	21.8	9.06	55				5.58
Cash from financing	17.4	6.36	35.7	26.6	19.4	55.6			34	3.2
Exchange rate effect	-0.01	0.03	-0.02	-0.01	0.03	-0.03	-0.02	0.01	-0.02	0.05
Net change in cash	1.6	-17.4	12.9	5.76	-3.7	36	-16.3	-17.9	0.52	-17.5
Free cash flow				-20.9	-23.1			-17.9	-33.4	-20.8

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.56 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Return on assets (ROA)	-188.0%	Net income / average total assets.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	1,135.0%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	131.1%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	64.6%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	-57.5%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	-35.4%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	-11.9%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	439.5%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	115.8%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	78.5%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	0.93x	Current assets / current liabilities.
Quick ratio	0.87x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	0.52x	(Cash + short-term investments) / current liabilities.
Liabilities / assets	85.3%	Total liabilities / total assets.
Working capital	-$712.0K	Current assets - current liabilities.
Goodwill and intangibles / assets	21.3%	(Goodwill + intangible assets) / total assets.

Per share

Metric	Value	How it is calculated
EPS, diluted	-$1.36	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share	-$1.06	Cash from operations / diluted weighted shares.
Cash per share	$0.33	(Cash + short-term investments) / shares outstanding.

Valuation

Metric	Value	How it is calculated
Market cap	$8.7M	Share price x shares outstanding.
Enterprise value	$3.6M	Market cap + total debt - cash - short-term investments.
Earnings yield	-249.3%	Net income / market cap (the inverse of P/E).

What was Traws Pharma, Inc.'s revenue in fiscal 2024?

Traws Pharma, Inc. reported revenue of $2.8M for fiscal 2024, 1,134.5% higher than the year before.

Was Traws Pharma, Inc. profitable in fiscal 2024?

Yes. Net income was $9.2M, a net margin of 328.7%.

How much free cash flow did Traws Pharma, Inc. generate in fiscal 2024?

Cash from operations of $18.2M minus capital expenditures of $2.6M left free cash flow of -$20.8M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to Traws Pharma, Inc.